1.37
+7.87%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Enlivex Therapeutics
Its shares trade under the ticker ENLV. It has been listed since 30 July 2014.
Enlivex Therapeutics Ltd. develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 30 Jul 2014
- Employees
- 34
- Website
- enlivex.com ↗
- Head office
- 37 DEREH MENACHEM BEGIN ST., TEL AVIV
- Incorporated in
- L3
- Classification
- Finance Services
- Filer status
- Non-accelerated filer
Leadership
Pay as last reported
- Dr. Oren HershkovitzChief Executive Officer$60,000
- Mr. Shai NovikExecutive Chairman of the Board, since 2014$536,000
- Prof. Dror MevorachFounder, Chief Scientific Officer and Medical Officer$545,000
- Mrs. Shachar ShlosbergerChief Financial Officer$132,000
- Mr. Baruch HalpertDirector$60,000
- Dr. Bernhard KirschbaumDirector
- Mr. Sangwoo LeeDirector
- Dr. Brian SchwartzDirector
- Mr. Michel HabibIndependent Director
- Dr. Gili HartIndependent Director
- Dr. Abraham HavronIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Enlivex Therapeutics Ltd has developed a promising portfolio of innovative immunotherapy products.
- The company has a strong team of experienced researchers and scientists who are skilled in developing and commercializing advanced therapies.
- Enlivex has established strategic partnerships with reputable organizations, enabling access to resources, expertise, and potential market opportunities.
Weaknesses
- Enlivex Therapeutics Ltd is a relatively young company, which may pose challenges in terms of financial stability and investor confidence.
- The company's product pipeline is currently limited, making it dependent on the successful development and approval of its existing candidates.
- Enlivex may face hurdles in terms of manufacturing and scaling up production to meet potential market demand.
Opportunities
- The field of immunotherapy is rapidly growing, providing Enlivex with opportunities to expand its product offerings and capture a share of the market.
- There is an increasing demand for novel therapies that can address unmet medical needs, creating a favorable market environment for Enlivex.
- The company can explore collaborations with pharmaceutical companies or research institutions to further advance its product development and accelerate commercialization.
Threats
- Enlivex faces competition from established players in the immunotherapy sector, which may limit its market penetration and revenue potential.
- Regulatory approvals and compliance requirements can pose significant challenges and delays in the development and commercialization of Enlivex's products.
- Changes in healthcare policies and reimbursement systems can impact the market adoption and affordability of Enlivex's immunotherapy solutions.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.